CA2757104C - Antagonistic il-17b receptor (il-17br) antibody - Google Patents

Antagonistic il-17b receptor (il-17br) antibody Download PDF

Info

Publication number
CA2757104C
CA2757104C CA2757104A CA2757104A CA2757104C CA 2757104 C CA2757104 C CA 2757104C CA 2757104 A CA2757104 A CA 2757104A CA 2757104 A CA2757104 A CA 2757104A CA 2757104 C CA2757104 C CA 2757104C
Authority
CA
Canada
Prior art keywords
antibody molecule
antibody
seq
domain
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2757104A
Other languages
English (en)
French (fr)
Other versions
CA2757104A1 (en
Inventor
Andrew Neil James Mckenzie
Daniel Neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Kingdom Research and Innovation
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of CA2757104A1 publication Critical patent/CA2757104A1/en
Application granted granted Critical
Publication of CA2757104C publication Critical patent/CA2757104C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2757104A 2009-04-06 2010-03-31 Antagonistic il-17b receptor (il-17br) antibody Active CA2757104C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16680809P 2009-04-06 2009-04-06
US61/166,808 2009-04-06
GBGB0905972.6A GB0905972D0 (en) 2009-04-06 2009-04-06 Antibodies against IL-17BR
GB0905972.6 2009-04-06
PCT/GB2010/000639 WO2010116123A1 (en) 2009-04-06 2010-03-31 Antibodies against il-17br

Publications (2)

Publication Number Publication Date
CA2757104A1 CA2757104A1 (en) 2010-10-14
CA2757104C true CA2757104C (en) 2018-07-24

Family

ID=40750206

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2757104A Active CA2757104C (en) 2009-04-06 2010-03-31 Antagonistic il-17b receptor (il-17br) antibody

Country Status (10)

Country Link
US (2) US8586037B2 (https=)
EP (1) EP2417161B1 (https=)
JP (1) JP5767625B2 (https=)
CN (1) CN102482352B (https=)
AU (1) AU2010233535B2 (https=)
CA (1) CA2757104C (https=)
DK (1) DK2417161T3 (https=)
ES (1) ES2633767T3 (https=)
GB (1) GB0905972D0 (https=)
WO (1) WO2010116123A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130209485A1 (en) * 2011-10-31 2013-08-15 Riken Therapeutic agent of non-allergic airway inflammation and/or non-allergic hyperresponsive airway
JP2015521591A (ja) 2012-06-12 2015-07-30 オレガ・バイオテック Ｉｌ−１７アイソフォームのアンタゴニストおよびその使用
EP2858670B8 (en) * 2012-06-12 2018-09-12 Orega Biotech Antagonists of il-17 isoforms and their uses
TW201613615A (en) * 2014-06-30 2016-04-16 Academia Sinica Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy
US10372718B2 (en) * 2014-11-03 2019-08-06 SavantX, Inc. Systems and methods for enterprise data search and analysis
EP3247396B1 (en) 2015-01-20 2024-08-28 Lankenau Institute for Medical Research Methods and compositions for the treatment of diseases and disorders
CN112955548B (zh) * 2018-07-09 2023-11-24 普众发现医药科技(上海)有限公司 叶酸受体α特异性抗体
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
EP3946377B1 (en) 2019-04-03 2025-12-10 Orega Biotech Combination therapies based on pd1 and il-17b inhibitors
WO2021170750A1 (en) 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
WO2025118126A1 (zh) * 2023-12-05 2025-06-12 中国抗体制药有限公司 抗il-17rb抗体、或其抗原结合片段或组合物的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0276846A3 (en) 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ES2379101T3 (es) * 1999-12-23 2012-04-20 Genentech, Inc. Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
WO2001057202A2 (en) 2000-02-04 2001-08-09 The Board Of Trustees Of The University Of Arkansas Evi27 gene sequences and protein encoded thereby
TWI322154B (en) * 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
BRPI0810561A2 (pt) 2007-04-23 2019-09-24 Wyeth Corp métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
US8454955B2 (en) 2007-11-28 2013-06-04 Riken Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia
WO2009136976A2 (en) * 2008-02-21 2009-11-12 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
JP2012522531A (ja) 2012-09-27
US20120020985A1 (en) 2012-01-26
EP2417161B1 (en) 2017-05-24
AU2010233535B2 (en) 2014-02-27
WO2010116123A1 (en) 2010-10-14
CA2757104A1 (en) 2010-10-14
CN102482352A (zh) 2012-05-30
CN102482352B (zh) 2015-06-10
HK1170745A1 (en) 2013-03-08
GB0905972D0 (en) 2009-05-20
EP2417161A1 (en) 2012-02-15
JP5767625B2 (ja) 2015-08-19
ES2633767T3 (es) 2017-09-25
US8586037B2 (en) 2013-11-19
AU2010233535A1 (en) 2011-11-03
DK2417161T3 (en) 2017-07-31
US8852589B2 (en) 2014-10-07
US20140044718A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
CA2757104C (en) Antagonistic il-17b receptor (il-17br) antibody
CN101711256B (zh) 针对il-25的抗体
EP2344538B1 (en) Antibodies against il-25
HK1170745B (en) Antibodies against il-17br
HK1154022B (en) Antibodies against il-25

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150306

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250318

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250318